A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms

Journal of Virology

Volumn 89, Issue 7, 2015, Pages 3712-3722

  Tan, Yunrui ^a   Ng, Qingyong ^a   Jia, Qiang ^a   Kwang, Jimmy ^a,b   He, Fang ^a  

^a Animal Health Biotechnology   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8A8; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VIRUS HEMAGGLUTININ; MUTANT PROTEIN; PROTEIN BINDING; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CELL FUSION; CONTROLLED STUDY; GENE MAPPING; GENE MUTATION; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; RECEPTOR BINDING; VIRUS DETECTION; VIRUS GENE; VIRUS NEUTRALIZATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DNA SEQUENCE; DRUG EFFECTS; EPITOPE MAPPING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); METABOLISM; PHYSIOLOGY; SERODIAGNOSIS; VIRUS ATTACHMENT; VIRUS ENTRY;

AVIAN INFLUENZA VIRUS; MURINAE; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BLOTTING, WESTERN; EPITOPE MAPPING; FLUORESCENT ANTIBODY TECHNIQUE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE, INBRED BALB C; MUTANT PROTEINS; NEUTRALIZATION TESTS; PROTEIN BINDING; SEQUENCE ANALYSIS, DNA; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 84924787169     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03014-14     Document Type: Article

References (46)

1. de Jong MD, Hien TT. 2006. Avian influenza A (H5N1). J Clin Virol 35:2-13. http://dx.doi.org/10.1016/j.jcv.2005.09.002.
2. Peiris JS, de Jong MD, Guan Y. 2007. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 20:243-267. http://dx.doi.org/10.1128/CMR.00037-06.
3. WHO. 27 July 2014, posting date. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2014. http://www.who.int/influenza/human_animal_interface/EN_GIP_20140727CumulativeNumberH5N1cases.pdf. WHO, Geneva, Switzerland.
4. Guan Y, Poon LL, Cheung CY, Ellis TM, Lim W, Lipatov AS, Chan KH, Sturm-Ramirez KM, Cheung CL, Leung YH, Yuen KY, Webster RG, Peiris JS. 2004. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci USA 101:8156-8161. http://dx.doi.org/10.1073/pnas.0402443101.
5. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420-428. http://dx.doi.org/10.1038/nature10831.
6. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. http://dx.doi.org/10.1038/4371108a.
7. Yen HL, Monto AS, Webster RG, Govorkova EA. 2005. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192:665-672. http://dx.doi.org/10.1086/432008.
8. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. 2013. H5N1 vaccines in humans. Virus Res 178:78-98. http://dx.doi.org/10.1016/j.virusres.2013.05.006.
9. Pica N, Palese P. 2013. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 64:189-202. http://dx.doi.org/10.1146/annurev-med-120611-145115.
10. He F, Kumar SR, Syed Khader SM, Tan Y, Prabakaran M, Kwang J. 2013. Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res 100:207-214. http://dx.doi.org/10.1016/j.antiviral.2013.08.003.
11. Xu W, Hofmann-Lehmann R, McClure HM, Ruprecht RM. 2002. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 20:1956-1960. http://dx.doi.org/10.1016/S0264-410X(02)00077-4.
12. Cao J, Meng S, Li C, Ji Y, Meng Q, Zhang Q, Liu F, Li J, Bi S, Li D, Liang M. 2008. Efficient neutralizing activity of cocktailed recombinant human antibodies against hepatitis A virus infection in vitro and in vivo. J Med Virol 80:1171-1180. http://dx.doi.org/10.1002/jmv.21212.
13. Meng W, Pan W, Zhang AJ, Li Z, Wei G, Feng L, Dong Z, Li C, Hu X, Sun C, Luo Q, Yuen KY, Zhong N, Chen L. 2013. Rapid generation of human-like neutralizing monoclonal antibodies in urgent preparedness for influenza pandemics and virulent infectious diseases. PLoS One 8:e66276. http://dx.doi.org/10.1371/journal.pone.0066276.
14. Laursen NS, Wilson IA. 2013. Broadly neutralizing antibodies against influenza viruses. Antiviral Res 98:476-483. http://dx.doi.org/10.1016/j.antiviral.2013.03.021.
15. Gamblin SJ, Skehel JJ. 2010. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403-28409. http://dx.doi.org/10.1074/jbc.R110.129809.
16. Eisen MB, Sabesan S, Skehel JJ, Wiley DC. 1997. Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutininsialyloligosaccharide complexes determined by X-ray crystallography. Virology 232:19-31. http://dx.doi.org/10.1006/viro.1997.8526.
17. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007.
18. Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69:531-569. http://dx.doi.org/10.1146/annurev.biochem.69.1.531.
19. Huston JS, George AJ. 2001. Engineered antibodies take center stage. Hum Antibodies 10:127-142.
20. Marasco WA, Sui J. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25:1421-1434. http://dx.doi.org/10.1038/nbt1363.
21. Xiong F, Xia L, Wang J, Wu B, Wang D, Yuan L, Cheng Y, Zhu H, Che X, Zhang Q, Zhao G, Wang Y. 2014. A high-affinity CDR-grafted antibody against influenza A H5N1 viruses recognizes a conserved epitope of H5 hemagglutinin. PLoS One 9:e88777. http://dx.doi.org/10.1371/journal.pone.0088777.
22. Perry LC, Jones TD, Baker MP. 2008. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D 9:385-396. http://dx.doi.org/10.2165/0126839-200809060-00004.
23. Prabakaran M, Ho HT, Prabhu N, Velumani S, Szyporta M, He F, Chan KP, Chen LM, Matsuoka Y, Donis RO, Kwang J. 2009. Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses. PLoS One 4:e4566. http://dx.doi.org/10.1371/journal.pone.0004566.
24. He F, Ho Y, Yu L, Kwang J. 2008. WSSV ie1 promoter is more efficient thanCMVpromoter to express H5 hemagglutinin from influenza virus in baculovirus as a chicken vaccine. BMC Microbiol 8:238. http://dx.doi.org/10.1186/1471-2180-8-238.
25. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497.
26. Prabhu N, Prabakaran M, Hongliang Q, He F, Ho HT, Qiang J, Goutama M, Lim AP, Hanson BJ, Kwang J. 2009. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza. Antivir Ther 14:911-921. http://dx.doi.org/10.3851/IMP1413.
27. He F, Kwang J. 2013. Monoclonal antibody targeting neutralizing epitope on H5N1 influenza virus of clade 1 and 0 for specific H5 quantification. Influenza Res Treat 2013:360675. http://dx.doi.org/10.1155/2013/360675.
28. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (ed). 1999. 1999 Current protocols in molecular biology. John Wiley and Sons, Inc., New York, NY.
29. Prabakaran M, He F, Meng T, Madhan S, Yunrui T, Jia Q, Kwang J. 2010. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J Virol 84:11822-11830. http://dx.doi.org/10.1128/JVI.00891-10.
30. Edwards MJ, Dimmock NJ. 2001. Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol 75:10208-10218. http://dx.doi.org/10.1128/JVI.75.21.10208-10218.2001.
31. Cao Z, Meng J, Li X, Wu R, Huang Y, He Y. 2012. The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus. PLoS One 7:e38126. http://dx.doi.org/10.1371/journal.pone.0038126.
32. He F, Madhan S, Kwang J. 2009. Baculovirus vector as a delivery vehicle for influenza vaccines. Expert Rev Vaccines 8:455-467. http://dx.doi.org/10.1586/erv.09.2.
33. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. 2006. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312:404-410. http://dx.doi.org/10.1126/science.1124513.
34. He F, Prabakaran M, Rajesh Kumar S, Tan Y, Kwang J. 2014. Monovalent H5 vaccine based on epitope-chimericHAprovides broad cross-clade protection against variant H5N1 viruses in mice. Antiviral Res 105:143-151. http://dx.doi.org/10.1016/j.antiviral.2014.03.002.
35. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251. http://dx.doi.org/10.1126/science.1171491.
36. Ekiert DC, Wilson IA. 2012. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol 2:134-141. http://dx.doi.org/10.1016/j.coviro.2012.02.005.
37. Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, van Oijen AM, Vogels R, Friesen RH. 2013. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 8:e80034. http://dx.doi.org/10.1371/journal.pone.0080034.
38. Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC. 2014. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J Virol 88:11726-11737. http://dx.doi.org/10.1128/JVI.01140-14.
39. He F, Du Q, Ho Y, Kwang J. 2009. Immunohistochemical detection of Influenza virus infection in formalin-fixed tissues with anti-H5 monoclonal antibody recognizing FFWTILKP. J Virol Methods 155:25-33. http://dx.doi.org/10.1016/j.jviromet.2008.09.016.
40. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37-43. http://dx.doi.org/10.1038/371037a0.
41. Oh HL, Akerstrom S, Shen S, Bereczky S, Karlberg H, Klingstrom J, Lal SK, Mirazimi A, Tan YJ. 2010. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 84:8275-8286. http://dx.doi.org/10.1128/JVI.02593-09.
42. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, Skepner E, Lewis NS, Spronken MI, Russell CA, Eropkin MY, Hurt AC, Barr IG, de Jong JC, Rimmelzwaan GF, Osterhaus AD, Fouchier RA, Smith DJ. 2013. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342:976-979. http://dx.doi.org/10.1126/science.1244730.
43. Bryson CJ, Jones TD, Baker MP. 2010. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 24:1-8. http://dx.doi.org/10.2165/11318560-000000000-00000.
44. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201. http://dx.doi.org/10.1093/bioinformatics/bti770.
45. Guex N, Peitsch MC, Schwede T. 2009. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 30(Suppl 1):S162-S173. http://dx.doi.org/10.1002/elps.200900140.
46. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. 2009. The SWISSMODEL repository and associated resources. Nucleic Acids Res 37:D387-D392. http://dx.doi.org/10.1093/nar/gkn750.